---
course_id: 20-102-macroepidemiology-be-102-spring-2005
layout: course_section
menu:
  leftnav:
    identifier: 00ccce44e6852e82c500168eb4144186
    name: Lecture Notes
    weight: 40
title: Lecture Notes
type: course
uid: 00ccce44e6852e82c500168eb4144186

---

The following table provides an outline of each lecture.

| lEc # | TOPICS |
| --- | --- |
| 1 | Introduction: Dimensions of information available to define the unknown causes of common diseases.  {{< br >}}  {{< br >}}1\. Four essential forms of information:  {{< br >}}  {{< br >}}(a) Public health records: historical changes in age-specific mortality and/or incidence.  {{< br >}}(b) Environmental epidemiology and community risk.  {{< br >}}(c) Population genetics and familial risk.  {{< br >}}(d) Human physiology and genetics.  {{< br >}}  {{< br >}}2\. Common theoretical structures:  {{< br >}}  {{< br >}}(a) Clonal expansion models: carcinogenesis and atherogenesis  {{< br >}}(b) Cell/function mortality models: diabetes, neural degenerative diseases  {{< br >}}  {{< br >}}3. Discussion of expectations and diseases of interest to class members. |
| 2 | Public health records and estimation of age-specific risk.  {{< br >}}  {{< br >}}1\. Introduction to birth cohort and age specific mortality and incidence data sets (see [Mortality Data](http://epidemiology.mit.edu/)).  {{< br >}}  {{< br >}}(a) Accuracy of the public record for mortality (MIT) and incidence (SEER) data  {{< br >}}(b) Accuracy of the U.S. census data.  {{< br >}}(c) Uncertainty in calculating an age-specific mortality or incidence rate: OBS (h,t)  {{< br >}}(d) Historical changes in diagnosis, prevention and therapy: S (h,t)  {{< br >}}(e) Historical changes in accuracy of recording causes of death: R (h,t)  {{< br >}}(f) Consideration of competing forms of death within an age interval: TOT (h,t)  {{< br >}}(g) Best (?) present estimate of age-specific expectation of risk for any disease: OBS (h,t)/{R (h,t) x \[1-S (h,t)\] x \[1-TOT (h,t)\]} |
| 3 | Effects of changes in diagnosis, prevention and therapy on historical mortality rates. Sources of differences in reported incidence and mortality.  {{< br >}}  {{< br >}}1. Early diagnoses: cervical, breast and prostate cancers.  {{< br >}}  {{< br >}}2. Prevention: food, water and medical microbiology hygiene; smoking avoidance.  {{< br >}}  {{< br >}}3. Therapy: antibiotics and infectious diseases. Chemotherapy and skin cancers, pediatric leukemia,  Hodgkin's lymphoma and adult chronic myelocytic leukemia. |
| 4 | Mathematical models derived from histopathological observations and age-specific mortality/incidence data. Examples: lung and colorectal cancers.  {{< br >}}  {{< br >}}1. Histology and histopathology of normal epithelium, preneoplasia and neoplasia: stemcells identified (?)  {{< br >}}  {{< br >}}2. The Armitage-Doll two (rate-limiting) stage model of carcinogenesis  {{< br >}}  {{< br >}}3. Genetic changes in carcinogenesis. (Some tested and untested hypotheses.)  {{< br >}}  {{< br >}}(a) Initiation  {{< br >}}(b) Promotion: required number of events "m", growth of preneoplasia, effect of stochastic factors on expected numbers of "cells at risk", rates of required genetic changes (if any).  {{< br >}}(c) Progression: invasion and metastases. Simplifying assumptions. |
| 5 | Initiation  {{< br >}}  {{< br >}}1\. Required number of events, "n".  {{< br >}}  {{< br >}}2. Growth of tissues.  {{< br >}}  {{< br >}}3. Concept of maintenance turnover units.  {{< br >}}  {{< br >}}4. Definition of "cells at risk".  {{< br >}}  {{< br >}}5. Rates of required genetic changes.  {{< br >}}  {{< br >}}6. Definition of Cinit(n). |
| 6 | Promotion and Progression  {{< br >}}  {{< br >}}1\. Promotion  {{< br >}}  {{< br >}}(a) Required number of events, "m".  {{< br >}}(b) Growth of number of cells at risk. Definition µ = (α-β).  {{< br >}}(c) Continuation of turnover units.  {{< br >}}(d) Rate of hypothetical required events.  {{< br >}}(e) Definition of Cprom(m).  {{< br >}}  {{< br >}}2\. Progression: Heterogeneity and general confusion of required genetic changes.  {{< br >}}  {{< br >}}3\. Demonstration of CancerFit Program. |
| 7 | Multiparametric Analysis of Colon Cancer  {{< br >}}  {{< br >}}1\. Somatic genetics of colon carcinogenesis. Assumption of n=2.  {{< br >}}  {{< br >}}2\. Range of parameters without limitation.  {{< br >}}  {{< br >}}3\. Limitations on parameters.  {{< br >}}  {{< br >}}(a) Minimum estimate of F ~ fraction of population with preneoplastic lesions, f = 1?  {{< br >}}(b) Absence of new polyps after age 60. Initiation limited to juvenile period?  {{< br >}}(c) Application of mutation and loss of heterozygosity levels in human organs.  {{< br >}}(d) Assumption that only stem cells are at risk.  {{< br >}}  {{< br >}}4\. Re-estimation of parameters using limitations derived from observations. |
| 8 | Multiparametric Analysis of Lung Cancer  {{< br >}}  {{< br >}}1\. Somatic genetics of lung carcinogenesis. Assumption of n=2.  {{< br >}}  {{< br >}}2\. Range of parameters without limitation.  {{< br >}}  {{< br >}}3\. Limitations on parameters.  {{< br >}}  {{< br >}}(a) Epidemiolgy of lung cancer: Rise of F with E, F=E?  {{< br >}}(b) Epidemiology of early death among smokers, f~1/6?  {{< br >}}(c) Fraction of smoking population with preneoplastic lesions.  {{< br >}}(d) Initiation limited to juvenile period?  {{< br >}}(e) Application of mutation and loss of heterozygosity levels in human organs.  {{< br >}}(f) Assumption that only stem cells are at risk.  {{< br >}}  {{< br >}}4\. Re-estimation of parameters using limitations derived from observations.  {{< br >}}  {{< br >}}5\. Testing of derived model among persons who quit smoking. |
| 9 | Role of Gender  {{< br >}}  {{< br >}}1. Growth periods  {{< br >}}  {{< br >}}2. Total stem cell number and/or gender-specific physiology/lifestyles. |
| 10 | Sub-populations at Risk  {{< br >}}  {{< br >}}1. Independence and/or intersections of inherited and environmental risks.  {{< br >}}  {{< br >}}2. Essential and accelerating risks.  {{< br >}}  {{< br >}}3. Stochastic risk. |
| 11 | National Risk and Community Risk  {{< br >}}  {{< br >}}1. National Risk  {{< br >}}  {{< br >}}(a) Comparative history of cancer rates among European, African Americans and Japanese.  {{< br >}}(b) Hypothetical role of post-agrarian environment versus genetic risk differences.  {{< br >}}  {{< br >}}2. Community Risk: Risk factors in Pennsylvania (1958-1995)  {{< br >}}  {{< br >}}(a) Use of binomial distribution to define expected age-specific mortality rates for any community in a state given the number of persons at risk and the average age specific mortality rate for the set of all communities in the state: null hypothesis that communities have identical cancer mortality rates.  {{< br >}}(b) Use of Kolmogorov-Smirnov analysis to discover significant differences between observed and expected distributions of mortality rates distributed over all communities. |
| 12 | Familial Risk Expectations  {{< br >}}  {{< br >}}1. Familial environmental risks: cultural and idiosyncratic habits  {{< br >}}  {{< br >}}2. Familial genetic risks: homozygous, heterozygous, nullizygous and functionally dominant risks.  {{< br >}}  {{< br >}}3. Siblings, dizygotic and monozygotic twins.  {{< br >}}  {{< br >}}4. Spouses.  {{< br >}}  {{< br >}}5. Parents and children.  {{< br >}}  {{< br >}}6. Pleiogenic risks. |
| 13 | Familial Risk Observations  {{< br >}}  {{< br >}}1. Parents and children  {{< br >}}  {{< br >}}2. Spouses  {{< br >}}  {{< br >}}3. Twins  {{< br >}}  {{< br >}}4. Pleiogenic risks |
| 14 | Population Genetics  {{< br >}}  {{< br >}}1. Age and size of human population.  {{< br >}}  {{< br >}}2. Rates of mutation.  {{< br >}}  {{< br >}}3. Rates of population growth and survival of neutral alleles.  {{< br >}}  {{< br >}}4. Dominant, recessive and non-deleterious conditions.  {{< br >}}  {{< br >}}5. Hardy-Weinberg equilibrium and expectations of allele frequencies. |
| 15 | Population Genetics (cont.)  {{< br >}}  {{< br >}}1. Allelic distributions and expected frequencies (see the [Human Gene Mutation Database](http://www.hgmd.org/))  {{< br >}}  {{< br >}}2. Generation of multiallelic risk by gametogenic mutations: mutational spectra.  {{< br >}}  {{< br >}}3. Expectations for deleterious mutational spectra.  {{< br >}}  {{< br >}}4. Expectations for non-deleterious spectra.  {{< br >}}  {{< br >}}5. Examples of multiallelic risk for deleterious conditions (~2000).  {{< br >}}  {{< br >}}6. Examples of mono-allelic risk for deleterious conditions (sickle cell anemia and cystic fibrosis)  {{< br >}}  {{< br >}}7. Example of multi-allelic risk for a common disease (MC1R and risk of skin cancer). |
| 16 | The search for genes carrying mutations conferring risk for common diseases.  {{< br >}}  {{< br >}}1. The assumption of mono-allelic risk and the resulting "great SNP hunt".  {{< br >}}  {{< br >}}2. The assumption of multi-allelic risk and the probable need for pangenomic scanning. |
| 17 | The search for genes carrying mutations conferring risk for common diseases. (cont.)  {{< br >}}  {{< br >}}1. Technology for DNA-based population genetic searches: multi-capillary DNA sequencers, SNP detectors and multi-capillary denaturing electrophoresis for multiple allele discovery.  {{< br >}}  {{< br >}}2. Costs and throughput: what is feasible and fundable?  {{< br >}}  {{< br >}}3. Strategy for pangenomic search for 100 common diseases: instrumentation, DNA samples and general statistical model. |
| 18 | The search for genes carrying mutations conferring risk for common diseases. (cont.)  {{< br >}}  {{< br >}}1. "Genicity" of risk.  {{< br >}}  {{< br >}}2. "Zygosity" of risk.  {{< br >}}  {{< br >}}3. "Ethnic stratification" and problem of mixedness.  {{< br >}}  {{< br >}}4. Potential use of "age-specific allelic decline" to identify genes carrying risk for mortal diseases. |
| 19 | The search for genes carrying mutations conferring risk for common diseases. (cont.)  {{< br >}}  {{< br >}}1. Using familial and general population risks for colon cancer to limit hypotheses. |
| 20 | The search for genes in which mutations of initiation (and promotion, if any) occur in common human cancers. |
| 21 | The origins of somatic and inherited mutations in humans.  {{< br >}}  {{< br >}}1. The environmental mutagen hypothesis.  {{< br >}}  {{< br >}}2. The search for environmental mutagens.  {{< br >}}  {{< br >}}3. The attempts to match in vitro human cell spectra with in vivo human tissue spectra.  {{< br >}}  {{< br >}}4. The discovery of dose-dependence of chemically induced mutational spectra.  {{< br >}}  {{< br >}}5. The discovery of shared subspectrum of human mutations with DNA methylating mutagens. |
| 22 | The origins of somatic and inherited mutations in humans. (cont.)  {{< br >}}  {{< br >}}1. Mutations of mitochondria and nuclear genes in smokers and non-smokers' lungs.  {{< br >}}  {{< br >}}2. Mutations of mitochondrial and nuclear genes by DNA polymerases.  {{< br >}}  {{< br >}}3. Possible restriction of somatic stem cell genetic changes to juvenile years: chromosomal translocations and point mutations as a function of age. |
| 23 | Hypotheses that need testing. (Professor turns 60 and looks to future.)  {{< br >}}  {{< br >}}1. Point mutation and chromosomal translocation mutations that initiate preneoplasia are restricted to years prior to metamorphosis to adult form in humans.  {{< br >}}  {{< br >}}2. DNA turnover in human stem and transitional cells involves a significant fraction of DNA each day.  {{< br >}}  {{< br >}}3. Point mutations in tissues are primarily generated by DNA polymerase errors during DNA synthesis and re-synthesis during DNA turnover in pre-adult stem cells.  {{< br >}}  {{< br >}}4. Environmental risk factors accelerate growth of preneoplastic lesions that arose in juvenile years.  {{< br >}}  {{< br >}}5. Environmental risk factors induce organ-specific inflammation.  {{< br >}}  {{< br >}}6. Genetic risks for common diseases are multi-allelic and commonly monogenic. |
| 24 | Evolution, embryogenesis and carcinogenesis. (Guest lecturer: Dr. Elena V. Gostjeva)  {{< br >}}  {{< br >}}1. Novel histologic preparation of tissues and high resolution microscopic images.  {{< br >}}  {{< br >}}2. Human embryogenesis: discovery of multiple nuclear morphotypes and "metakaryotic" modes of nuclear division.  {{< br >}}  {{< br >}}3. Human embryogenesis: discovery of asymmetric metakaryotic nuclear divisions: evidence of organogenic stem cell behavior.  {{< br >}}  {{< br >}}4. Human carcinogenesis: normal, preneoplastic and neoplastic histology.  {{< br >}}  {{< br >}}5. Human carcinogenesis: persistence of juvenile phenotype and transformation to fetal phenotype.  {{< br >}}  {{< br >}}6. Potential for high risk of genetic change in metakaryotic DNA synthesis and chromosomal segregation.  {{< br >}}  {{< br >}}7. Evolutionary origin of metakaryotic phenotype.  {{< br >}}  {{< br >}}Putting it together: Gostjeva-Thilly cascade model for risk and genesis of common clonal diseases. |
| 25-27 | General discussion and student presentations.  {{< br >}}  {{< br >}}Students are encouraged to invite academic advisors and friends to presentations.